Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to E/C/F/TAF in Older HIV-1 Patients
NCT02616783Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Percent Change From Baseline to Week 48 in Spine Bone Mineral Density and Percent Change From Baseline to Week 48 in Hip Bone Mineral Density. Started Dec 2015; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02616783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616783.